A clinically and genomically annotated nerve sheath tumor biospecimen repository.


Journal

Scientific data
ISSN: 2052-4463
Titre abrégé: Sci Data
Pays: England
ID NLM: 101640192

Informations de publication

Date de publication:
19 06 2020
Historique:
received: 20 12 2019
accepted: 12 05 2020
entrez: 21 6 2020
pubmed: 21 6 2020
medline: 5 11 2020
Statut: epublish

Résumé

Nerve sheath tumors occur as a heterogeneous group of neoplasms in patients with neurofibromatosis type 1 (NF1). The malignant form represents the most common cause of death in people with NF1, and even when benign, these tumors can result in significant disfigurement, neurologic dysfunction, and a range of profound symptoms. Lack of human tissue across the peripheral nerve tumors common in NF1 has been a major limitation in the development of new therapies. To address this unmet need, we have created an annotated collection of patient tumor samples, patient-derived cell lines, and patient-derived xenografts, and carried out high-throughput genomic and transcriptomic characterization to serve as a resource for further biologic and preclinical therapeutic studies. In this work, we release genomic and transcriptomic datasets comprised of 55 tumor samples derived from 23 individuals, complete with clinical annotation. All data are publicly available through the NF Data Portal and at http://synapse.org/jhubiobank.

Identifiants

pubmed: 32561749
doi: 10.1038/s41597-020-0508-5
pii: 10.1038/s41597-020-0508-5
pmc: PMC7305302
doi:

Types de publication

Dataset Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

184

Références

Korf, B. R. Plexiform neurofibromas. Am. J. Med. Genet. 89, 31–37 (1999).
doi: 10.1002/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W
Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431, https://doi.org/10.1054/bjoc.2001.1796 (2001).
doi: 10.1054/bjoc.2001.1796 pubmed: 11355958 pmcid: 2363645
Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338–350, https://doi.org/10.1038/nrclinonc.2012.61 (2012).
doi: 10.1038/nrclinonc.2012.61 pubmed: 22508028 pmcid: 3928688
Cichowski, K. et al. Mouse models of tumor development in neurofibromatosis type 1. Science 286, 2172–2176 (1999).
doi: 10.1126/science.286.5447.2172
Le, L. Q. & Parada, L. F. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene 26, 4609–4616, https://doi.org/10.1038/sj.onc.1210261 (2007).
doi: 10.1038/sj.onc.1210261 pubmed: 17297459 pmcid: 2760340
N.C.I. National Cancer Institute (NCI); Division of Cancer Treatment & Diagnosis. Cancer Diagnosis Program — BBRB Biorepositories & Biospecimen Research Branch: Best Practices, https://biospecimens.cancer.gov/bestpractices/ (2018).
Allaway, R. J. et al. Engaging a community to enable disease-centric data sharing with the NF Data Portal. Sci. Data 6, 319, https://doi.org/10.1038/s41597-019-0317-x (2019).
doi: 10.1038/s41597-019-0317-x pubmed: 31836719 pmcid: 6910996
Gosline, S. J. et al. A high-throughput molecular data resource for cutaneous neurofibromas. Sci. Data 4, 170045, https://doi.org/10.1038/sdata.2017.45 (2017).
doi: 10.1038/sdata.2017.45 pubmed: 28398289 pmcid: 5387919
Ferrer, M. et al. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Sci. Data 5, 180106, https://doi.org/10.1038/sdata.2018.106 (2018).
doi: 10.1038/sdata.2018.106 pubmed: 29893754 pmcid: 5996849
Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1, https://doi.org/10.1186/gb-2011-12-1-r1 (2011).
doi: 10.1186/gb-2011-12-1-r1 pubmed: 21205303 pmcid: 3091298
(How to part I) Sensitively detect copy ratio alterations and allelic segments, https://software.broadinstitute.org/gatk/documentation/article?id=11682 (2018).
Poplin, R. et al. A universal SNP and small-indel variant caller using deep neural networks. Nat. Biotechnol. 36, 983–987, https://doi.org/10.1038/nbt.4235 (2018).
doi: 10.1038/nbt.4235 pubmed: 30247488
Quinlan, A. R. BEDTools: The Swiss-Army Tool for Genome Feature Analysis. Curr Protoc Bioinformatics 47, 11 12 11-34, https://doi.org/10.1002/0471250953.bi1112s47 (2014).
Wingett, S. W. & Andrews, S. FastQ Screen: A tool for multi-genome mapping and quality control. F1000Res 7, 1338, https://doi.org/10.12688/f1000research.15931.2 (2018).
doi: 10.12688/f1000research.15931.2 pubmed: 6124377 pmcid: 6124377
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419, https://doi.org/10.1038/nmeth.4197 (2017).
doi: 10.1038/nmeth.4197 pubmed: 28263959 pmcid: 5600148
Pollard, K. et al. JHU Biobank raw counts. Synapse https://doi.org/10.7303/syn19522967 (2020).
Pollard, K. et al. JHU Biobank harmonized RNAseq counts and metadata. Synapse https://doi.org/10.7303/syn20812185.1 (2020).
Gosline, S. B., J; Allaway, R; Guo, X; Doan, X. Sage-Bionetworks/JHU-biobank: JHU Biobank Code Repository. Zenodo https://doi.org/10.5281/zenodo.3726380 (2020).
Pratilas, C. A., Pollard, K. & Wang, J. A Nerve Sheath Tumor Bank from Patients with NF1. Synapse https://doi.org/10.7303/syn4939902 (2020).
Kourea, H. P., Orlow, I., Scheithauer, B. W., Cordon-Cardo, C. & Woodruff, J. M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am. J. Pathol. 155, 1855–1860, https://doi.org/10.1016/S0002-9440(10)65504-6 (1999).
doi: 10.1016/S0002-9440(10)65504-6 pubmed: 10595915 pmcid: 1866948
Lee, W. et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1227–1232, https://doi.org/10.1038/ng.3095 (2014).
doi: 10.1038/ng.3095 pubmed: 25240281 pmcid: 25240281
Zhang, M. et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1170–1172, https://doi.org/10.1038/ng.3116 (2014).
doi: 10.1038/ng.3116 pubmed: 25305755 pmcid: 4383254
Hirbe, A. C. et al. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol. 16, 466–467, https://doi.org/10.1093/neuonc/not248 (2014).
doi: 10.1093/neuonc/not248 pubmed: 24366910
Carroll, S. L. The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am. J. Pathol. 186, 464–477, https://doi.org/10.1016/j.ajpath.2015.10.023 (2016).
doi: 10.1016/j.ajpath.2015.10.023 pubmed: 26740486 pmcid: 4816695
Hirbe, A. C. et al. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer 123, 1194–1201, https://doi.org/10.1002/cncr.30455 (2017).
doi: 10.1002/cncr.30455 pubmed: 27875628
Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv, https://arxiv.org/abs/1303.3997 (2013).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079, https://doi.org/10.1093/bioinformatics/btp352 (2009).
doi: 10.1093/bioinformatics/btp352 pubmed: 2723002 pmcid: 2723002
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303, https://doi.org/10.1101/gr.107524.110 (2010).
doi: 10.1101/gr.107524.110 pubmed: 2928508 pmcid: 2928508
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498, https://doi.org/10.1038/ng.806 (2011).
doi: 10.1038/ng.806 pubmed: 21478889 pmcid: 3083463
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164, https://doi.org/10.1093/nar/gkq603 (2010).
doi: 10.1093/nar/gkq603 pubmed: 2938201 pmcid: 2938201

Auteurs

Kai Pollard (K)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.

Jineta Banerjee (J)

Sage Bionetworks, Seattle, USA.

Xengie Doan (X)

Sage Bionetworks, Seattle, USA.

Jiawan Wang (J)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.

Xindi Guo (X)

Sage Bionetworks, Seattle, USA.

Robert Allaway (R)

Sage Bionetworks, Seattle, USA.

Shannon Langmead (S)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA.

Bronwyn Slobogean (B)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA.

Christian F Meyer (CF)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.

David M Loeb (DM)

Albert Einstein College of Medicine, New York, USA.

Carol D Morris (CD)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, USA.

Allan J Belzberg (AJ)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA.
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA.

Jaishri O Blakeley (JO)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA.
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA.

Fausto J Rodriguez (FJ)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.

Justin Guinney (J)

Sage Bionetworks, Seattle, USA.

Sara J C Gosline (SJC)

Sage Bionetworks, Seattle, USA. sara.gosline@sagebionetworks.org.

Christine A Pratilas (CA)

Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA. cpratil1@jhmi.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH